Patricia Spilman

1.9k citations

26 papers · 1.5k indexed · 1 hit paper · h-index 15

Physiology top 5%
Molecular Biology top 10%
Epidemiology top 10%
Pharmacology top 5%
Neurology top 5%

Co-authors: Dale E. Bredesen Olivia Gorostiza Verónica Galván Matthew J. Hart Natalia Podlutskaya Arlan Richardson Jayanta Debnath Randy Strong
Topics: Alzheimer's disease research and treatments (15 papers)Cholinesterase and Neurodegenerative Diseases (7 papers)Computational Drug Discovery Methods (6 papers)
Cited by: Aging Physiology Biological Psychiatry
Journals: Journal of Neuroscience PLoS ONE Journal of Molecular Biology
Partner nations: United States France Japan

In The Last Decade

Patricia Spilman

25 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease

2010 807 citations Patricia Spilman, Natalia Podlutskaya et al. PLoS ONE profile →

Peers

Countries citing papers authored by Patricia Spilman

Since Specialization

Citations

This map shows the geographic impact of Patricia Spilman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia Spilman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia Spilman more than expected).

Fields of papers citing papers by Patricia Spilman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patricia Spilman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia Spilman. The network helps show where Patricia Spilman may publish in the future.

Co-authorship network of co-authors of Patricia Spilman

This figure shows the co-authorship network connecting the top 25 collaborators of Patricia Spilman. A scholar is included among the top collaborators of Patricia Spilman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia Spilman. Patricia Spilman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of an APP-selective BACE1 inhibitor for Alzheimer's disease 2025 ·Neurotherapeutics ·Jesus Campagna,(unknown),(unknown),Chunni Zhu,Jessica Lee,Whitaker Cohn,(unknown),(unknown),(unknown),Olivier Descamps,Clare Peters‐Libeu,Qiang Zhang,Olivia Gorostiza,Karen S. Poksay,Patricia Spilman,Dale E. Bredesen,Varghese John	0
2	Correction to: Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson’s disease model 2021 ·Molecular Brain ·Chunni Zhu,Tina Bilousova,(unknown),(unknown),(unknown),Mikhail Melnik,Sujyoti Chandra,Jesus Campagna,Whitaker Cohn,Asa Hatami,Patricia Spilman,Karen H. Gylys,Varghese John	4
3	Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson’s disease model 2021 ·Molecular Brain ·Chunni Zhu,Tina Bilousova,(unknown),(unknown),(unknown),Mikhail Melnik,Sujyoti Chandra,Jesus Campagna,Whitaker Cohn,Asa Hatami,Patricia Spilman,Karen H. Gylys,Varghese John	20
4	A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer’s disease mouse model 2018 ·Scientific Reports ·Jesus Campagna,Patricia Spilman,(unknown),Dongsheng Bai,Asa Hatami,Chunni Zhu,Tina Bilousova,(unknown),(unknown),(unknown),Gregory M. Cole,Mary Jo LaDu,Michael E. Jung,Dale E. Bredesen,Varghese John	30
5	Evaluation of an Allosteric BACE Inhibitor Peptide to Identify Mimetics that Can Interact with the Loop F Region of the Enzyme and Prevent APP Cleavage 2018 ·Journal of Molecular Biology ·Jesus Campagna,Kanagasabai Vadivel,(unknown),(unknown),Tina Bilousova,Patricia Spilman,Varghese John	8
6	Screening for Small Molecule Inhibitors of Statin-Induced APP C-terminal Toxic Fragment Production 2017 ·Frontiers in Pharmacology ·Karen S. Poksay,Douglas J. Sheffler,Patricia Spilman,Jesus Campagna,(unknown),Olivier Descamps,Olivia Gorostiza,(unknown),Michael C. Mullenix,Dale E. Bredesen,Nicholas D. P. Cosford,Varghese John	3
7	C O bond formation in a microfluidic reactor: high yield S N Ar substitution of heteroaryl chlorides 2016 ·Tetrahedron Letters ·(unknown),(unknown),Jesus Campagna,Patricia Spilman,(unknown)	14
8	Netrin-1 Interrupts Amyloid-β Amplification, Increases sAβPPα in vitro and in vivo, and Improves Cognition in a Mouse Model of Alzheimer’s Disease 2016 ·Journal of Alzheimer s Disease ·Patricia Spilman,Véronique Corset,Olivia Gorostiza,Karen S. Poksay,Verónica Galván,Junli Zhang,Rammohan V. Rao,Clare Peters‐Libeu,Jon Vincelette,Andrew McGeehan,(unknown),Janine Beyer,Jesus Campagna,(unknown),(unknown),Varghese John,Dale E. Bredesen	27
9	Direct Transcriptional Effects of Apolipoprotein E 2016 ·Journal of Neuroscience ·Veena Theendakara,Clare Peters‐Libeu,Patricia Spilman,Karen S. Poksay,Dale E. Bredesen,Rammohan V. Rao	111
10	The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model 2014 ·Brain Research ·Patricia Spilman,Olivier Descamps,Olivia Gorostiza,Clare Peters‐Libeu,Karen S. Poksay,(unknown),Jesus Campagna,(unknown),Rammohan V. Rao,Varghese John,Dale E. Bredesen	34
11	AβPP-Selective BACE Inhibitors (ASBI): Novel Class of Therapeutic Agents for Alzheimer's Disease 2013 ·Journal of Alzheimer s Disease ·Olivier Descamps,Patricia Spilman,Qiang Zhang,Clare Peters Libeu,Karen S. Poksay,Olivia Gorostiza,Jesus Campagna,(unknown),Dale E. Bredesen,Varghese John	22
12	The small co-chaperone p23 overexpressing transgenic mouse 2012 ·Journal of Neuroscience Methods ·Junli Zhang,Patricia Spilman,Sylvia Chen,Olivia Gorostiza,(unknown),Kayvan Niazi,Dale E. Bredesen,Rammohan V. Rao	2
13	S4‐04‐04: The APP ligand Netrin‐1 improves memory and biomarkers after ICV administration in PD APP mice 2012 ·Alzheimer s & Dementia ·Patricia Spilman,Jon Vincelette,Andrew McGeehan,Olivia Gorostiza,Karen S. Poksay,(unknown),(unknown),Sherry Bullens,Varghese John,(unknown),Stuart Bunting,Dale E. Bredesen	1
14	Correction: Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease 2011 ·PLoS ONE ·Patricia Spilman,Natalia Podlutskaya,Matthew J. Hart,Jayanta Debnath,Olivia Gorostiza,Dale E. Bredesen,Arlan Richardson,Randy Strong,Verónica Galván	2
15	Endogenously EGFP-Labeled Mouse Embryonic Stem Cells. 2011 ·PubMed ·Junli Zhang,Rammohan V. Rao,Patricia Spilman,(unknown),Lin Xie,Cathy Vitelli,Olivia Gorostiza,David T. Madden,Xianmin Zeng,Kunlin Jin,Matthew J. Hart,Dale E. Bredesen,Verónica Galván	4
16	Correction: Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease 2011 ·PLoS ONE ·Patricia Spilman,Natalia Podlutskaya,Matthew J. Hart,Jayanta Debnath,Olivia Gorostiza,Dale E. Bredesen,Arlan Richardson,Randy Strong,Verónica Galván	1
17	Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Diseasebreakdown → 2010 ·PLoS ONE ·Patricia Spilman,Natalia Podlutskaya,Matthew J. Hart,Jayanta Debnath,Olivia Gorostiza,Dale E. Bredesen,Arlan Richardson,Randy Strong,Verónica Galván	807
18	In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid β-peptide of APP 2009 ·Free Radical Biology and Medicine ·D. Allan Butterfield,Verónica Galván,(unknown),Huidong Tang,Renã A. Sowell,Patricia Spilman,Joanna Fombonne,Olivia Gorostiza,Junli Zhang,Rukhsana Sultana,Dale E. Bredesen	166
19	Interaction of ASK1 and the β-amyloid precursor protein in a stress-signaling complex 2007 ·Neurobiology of Disease ·Verónica Galván,Surita Banwait,Patricia Spilman,Olivia Gorostiza,Alyson Peel,(unknown),Danielle Crippen,Wei Huang,(unknown),Hidenori Ichijo,Dale E. Bredesen	17
20	PrP^cGlycoform Heterogeneity as a Function of Brain Region: Implications for Selective Targeting of Neurons by Prion Strains 1999 ·Journal of Neuropathology & Experimental Neurology ·Stephen J. DeArmond,Yin Long Qiu,Henry Sánchez,Patricia Spilman,(unknown),Darwin O. V. Alonso,Valerie Daggett	97

About Patricia Spilman

Patricia Spilman is a scholar working on Aging, Physiology and Pharmacology, having authored 26 papers that have together received 1.5k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (15 papers), Cholinesterase and Neurodegenerative Diseases (7 papers) and Computational Drug Discovery Methods (6 papers). The work is most often cited by research in Aging (114 citations), Physiology (767 citations) and Biological Psychiatry (68 citations). Patricia Spilman has collaborated with scholars based in United States, France and Japan. Frequent co-authors include Dale E. Bredesen, Olivia Gorostiza, Verónica Galván, Matthew J. Hart, Natalia Podlutskaya, Arlan Richardson, Jayanta Debnath, Randy Strong, Karen S. Poksay and Clare Peters‐Libeu. Their work appears in journals such as Journal of Neuroscience, PLoS ONE and Journal of Molecular Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact